Analyst Report: LMT

1. EXECUTIVE SUMMARY

Lockheed Martin closed at $622.99 on Tuesday October 27, up 13.54% over the week from $548.71 on October 20, after a third-quarter beat, a second raised 2026 outlook and an F-35 framework on Thursday October 22 (+6.96%), followed by a Morgan Stanley upgrade on Monday October 26 (+5.13%). The shares fell 1.92% on October 27, a session for which the research brief identifies no company catalyst. Fundamentals support part of the rerating: record backlog of $292bn, guidance for sales of $80bn to $82bn, and removal of the worry that F-35 funding would be diverted to missiles. The F-35 framework is not yet an order and needs congressional authority, so some of the move prices in a decision that has not been made. The stock now trades at a forward P/E of 18.7 and sits above both its 50-day and 200-day averages.

2. THE CATALYST

The first leg came on Thursday October 22, when the stock gained 6.96% on volume of 2,957,700 shares. Lockheed reported third-quarter EPS of $7.97 against a $7.52 consensus, and revenue of $20.7bn against forecasts of about $20.48bn (Investing.com, October 22).

Guidance was lifted for a second straight quarter. On the same day Lockheed unveiled an F-35 framework covering 850 U.S. aircraft over 10 years, plus international orders across Lots 21 to 30, at 156 aircraft a year (Lockheed Martin newsroom, Oct 22). The company said the framework needs multiyear authority and appropriations from Congress before a formal award, with pricing and terms set at that stage (JPost and Lockheed Martin newsroom, Oct 22). The U.S. Department of War release describes the framework as "finalized" and says Lockheed will self-fund at least $7bn of F-35-related initiatives, while the company and the press call it nonbinding. The brief also records conflicting PAC-3 figures: one source gives $52.5bn, another says the seven-year contract could total $58.6bn (Investing.com).

The second leg came on Monday October 26 (+5.13%, volume 2,666,700). Morgan Stanley's Kristine Liwag upgraded the shares to Overweight from Equal-weight and raised the price target to $835 from $690. The note said the F-35 deal removes a key risk, which was investor concern that F-35 funding could be cut to pay for missiles. It cited a 4.0x risk/reward skew and mid-teens five-year growth in Missiles and Fire Control (Investing.com, October 26). Seeking Alpha reported a premarket gain of about 1.2%, so most of the move came later in the session (single source). Trefis says the October 22 and October 26 gains are the two largest single-session moves in a year.

On October 27 the stock fell 1.92% on volume of 2,223,900. Trefis states Lockheed made no new announcements or filings that day. A Yahoo Finance item reports a $694M Air Force contract for the ARRW hypersonic missile, but the brief could read only its description and found no evidence it moved the shares, so this is unconfirmed.

3. COMPANY PROFILE

Lockheed Martin is an aerospace and defense contractor in the Industrials sector, operating through four segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems, and Space. Its peers in the panel are Boeing, GE, RTX, Howmet, Northrop Grumman and General Dynamics. The market capitalisation is $143.91bn and the dividend yield is 2.27%.

Third-quarter details from the brief:

• MFC sales rose 24% to $4.5bn on PAC-3, THAAD, GMLRS and PrSM ramps (Quartz).
• Aeronautics sales rose 13% to $8.2bn, including a $710M increase on the F-35 program (Quartz).
• Free cash flow was $3.0bn, below $3.3bn a year earlier (GuruFocus).
• Management trimmed its 2026 Aeronautics forecast slightly because it expects the next F-35 contracts to be awarded later (Trefis).
• The dividend rose for a 24th straight year (Tickeron).
• The $3.45bn Ultra Maritime acquisition has completed (Defense World, single source).

4. DEEP DIVE ANALYSIS

Do fundamentals justify the move? Part of it. The earnings beat, higher guidance and record backlog are concrete and explain the October 22 session. The Morgan Stanley upgrade moved the stock on October 26 without new company data. The framework itself carries no pricing and no appropriation, and the brief notes that Lot 20 is excluded from 2026 guidance and that its costs have already exceeded current contractual authorization (247 Wall St., single source). Lots 20 and higher remain under negotiation.

Peers. Over the move period the peers in the panel diverged: NOC +3.23%, GD +3.03%, RTX +0.65%, GE -0.74%, HWM -9.28% and BA -11.70%. Lockheed's 13.54% gain is well ahead of the defence names, so the rise is specific to the company. Trefis notes that four of five peers rose on October 26 and that Lockheed rose more than any of them. A Motley Fool headline attributed Boeing's October 27 drop to lower production rates and missed deliveries (headline only). The S&P 500 gained 0.13% over the period.

Context. On October 20 defence stocks sold off on expectations of a Democratic sweep of Congress (247 Wall St., headline only), which places the weekly starting point near a local low. The most relevant comparable in the brief is January 2019, when Morgan Stanley downgraded Lockheed on F-35 production concerns (Motley Fool). The 2026 upgrade comes from the same bank on the reverse view of the same program.

Bull case. Backlog is at a record, MFC is growing at a double-digit pace, free cash flow guidance is raised, and Morgan Stanley's $835 target implies room above the current price. UBS raised its target to $692 from $653 with a Buy rating (Yahoo Finance headline, October 23). Consensus targets cited are $645.48 from 23 analysts (247 Wall St.) and $633.62 (MarketScreener), which sit close to the current price.

Bear case. The F-35 framework depends on Congress. Third-quarter free cash flow fell year on year. Lockheed has not repurchased shares, which Defense World says limits a near-term capital-return catalyst. RBC raised its target to $600 from $550 with a Sector Perform rating (date unconfirmed), a figure below the current price. After a 21.63% rise in 20 sessions, the shares trade near the consensus targets.

5. TECHNICAL SNAPSHOT

The close of $622.99 sits above the 50-day average of $540.55 and the 200-day average of $562.06, and stands 8.8% below the 52-week high of $683.27 set on March 2. The stock is 45.1% above the 52-week low of $429.47. The October 26 close of $635.20 is the nearest resistance, and the October 23 close of $604.18 is the nearest support, with $589.91 from October 22 below it. Volume of 2,223,900 on October 27 was 1.81x the 50-session average of 1,230,278, so the pullback came on heavy trading, as did the three advance days.

6. RISK FACTORS

• Congress has not set a date for multiyear F-35 authority and appropriations, which Lockheed expects "in the coming months" (Lockheed Martin newsroom).
• Later F-35 awards already trimmed the 2026 Aeronautics forecast.
• The framework's status is disputed between the Department of War and the company.
• Lot 20 costs exceed current authorization and sit outside guidance.
• The October 20 sell-off on expectations of a Democratic Congress shows political risk to defence budgets.
• The 2027 outlook comes with fourth-quarter results in January 2027, and Trefis names the 2027 sales forecast as the figure to watch.

7. ACTIONABLE OUTLOOK

Short term (1-2 weeks). The stock has had two of its largest daily gains in a year and then a pullback on heavy volume with no sourced catalyst. Trading around $604 to $635 is the range set by recent closes. A close above $635.20 would extend the advance, while a close below $604.18 would open a retest of $589.91.

Medium term (1-3 months). The direction depends on congressional action on F-35 multiyear authority, for which no date exists, and on any detail on Lot 20 and higher negotiations. Progress on those items would support the Morgan Stanley view, and delay would weigh on the Aeronautics outlook.

Long term. The thesis has improved on backlog, MFC growth and raised guidance, and the F-35 funding worry has eased. The conversion of the framework into funded orders is still open, and the January 2027 guidance will test it. This is analysis only and not personal financial advice.